thyrotropin
Trade name: Thyropar
Biologicalapproved
Approved
May 26, 1953
Thyroid-stimulating hormone (also known as thyrotropin, thyrotropic hormone, or abbreviated TSH) is a pituitary hormone that stimulates the thyroid gland to produce thyroxine (T4), and then triiodothyronine (T3) which stimulates the metabolism of almost every tissue in the body. It is a glycoprotein hormone produced by thyrotrope cells in the anterior pituitary gland, which regulates the endocrine function of the thyroid. — Wikipedia
Clinical trial activity
21 trials · 19 clinical orgs · 2 marketing orgs
Phase 1
4
Phase 2
14
Phase 3
5
Phase 4
1
Earliest trial started Apr 1, 2002 (NCT00145366)
Timeline
1950s
- May 26, 1953
Pasteur Merieux — Earliest FDA Approval
- May 26, 1953
Sanofi-Aventis — NDA Secondary Org
- May 26, 1953
Pasteur Merieux — NDA Organization
Indications
Approved for
Mechanism of action
- Thyrotropin subunit betaSupplementation
TSHB supplementation
Approval history
- approvedMay 26, 1953
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaThyroid-stimulating hormone ↗
- NCATS02KSI6Z9AK ↗
- ChEMBLCHEMBL1201532 ↗
Also known as
- rtsh
- thyroid stimulating hormone
- thyroid stimulating hormone
- thyroid stimulating hormone
- thyroid-stimulating hormone
- thyropar
- thyrotrophin
- thyrotrophin
- thyrotrophin-alfa
- thyrotrophin-alpha
- thyrotropin
- thyrotropin
- thyrotropin
- thyrotropin
- thyrotropin
- thyrotropin
- thyrotropin-a
- thyrotropin alfa
- thyrotropin alpha
- thyrotropin-alpha
- thytropar
- thytrophin
- tsh
- tsh
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06431620 | N/A | Jun 30, 2024 | Nanjing Medical University |
| NCT06405217 | N/A | Apr 20, 2024 | Nanjing Medical University |
| NCT05668962 | Phase 2 | Jan 31, 2023 | Eli Lilly, Harvard University |
| NCT04964284 | Phase 3 | Jan 31, 2022 | Chinese Academy of Medical Sciences, Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT04971473 | Phase 3 | Dec 31, 2021 | Chinese Academy of Medical Sciences, Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT04447183 | Phase 2 | Dec 1, 2020 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT04137185 | Phase 1/Phase 2 (Phase 2) | Jun 10, 2019 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT03244956 | Phase 2 | Jul 31, 2017 | Institut Gustave Roussy |
| NCT02278198 | Phase 1 | Nov 1, 2014 | University of Colorado, Denver |
| NCT02145143 | N/A | May 1, 2014 | Cornell University, Genentech |
| NCT01909141 | Early Phase 1 (Phase 1) | Aug 1, 2013 | Cairo University |
| NCT01837745 | Phase 3 | Apr 1, 2013 | Institut Gustave Roussy |
| NCT00604318 | Phase 4 | Feb 1, 2008 | University of Copenhagen, University of Southern Denmark |
| NCT00454220 | Phase 2 | Jul 1, 2007 | Genzyme |
| NCT00435851 | Phase 3 | Feb 1, 2007 | Institut Gustave Roussy, National Cancer Institute, France |
| NCT00415233 | Phase 3 | Nov 1, 2006 | Newcastle University, University of London |
| NCT00275171 | Phase 2 | Feb 1, 2006 | University of Southern Denmark |
| NCT00137891 | Phase 1 | Jun 1, 2005 | Genzyme |
| NCT00181168 | Phase 2 | Mar 1, 2005 | Genzyme, Institut Gustave Roussy, Johns Hopkins University, University of Texas at Houston |
| NCT00085293 | Phase 2 | May 1, 2004 | National Cancer Institute (NCI), University of Texas at Houston |
Showing 20 of 21 trials
Page 1 / 2
Organizations
Research & Development (19)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Institut Gustave Roussy | Academic/Hospital | 4 | 3 | 2 | 2005 |
| Suzhou Zelgen Biopharmaceuticals Co.,Ltd | For profit | 4 | 4 | 2 | 2019 |
| Genzyme | For profit | 3 | 2 | 2 | 2005 |
| University of Southern Denmark | Academic/Hospital | 3 | 2 | 2 | 2002 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 0 | 1 | 2021 |
| Nanjing Medical University | Academic/Hospital | 2 | 2 | 1 | 2024 |
| University of Texas at Houston | Academic/Hospital | 2 | 0 | 1 | 2004 |
| Cairo University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Eli Lilly | For profit | 1 | 0 | 1 | 2023 |
| Genentech | For profit | 1 | 0 | 1 | 2014 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2005 |
| National Cancer Institute, France | Government | 1 | 0 | 1 | 2007 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2004 |
| Newcastle University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Colorado, Denver | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of Copenhagen | Academic/Hospital | 1 | 1 | 1 | 2008 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2006 |
19 organizations
Page 1 / 1
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Pasteur Merieux | For profit | NDA | May 26, 1953 |
| Sanofi-Aventis | For profit | NDA2 | May 26, 1953 |